By Fineline Cube 
GemPharmatech Inc., (SHA: 688046) a global leader in pre‑clinical research solutions and genetically‑engineered mouse models, today announced a non‑exclusive collaboration with the Memorial Sloan Kettering Cancer Center (MSKCC). The partnership unlocks GemPharmatech’s NeoMab platform—an advanced transgenic mouse system—enabling MSKCC scientists to expedite the discovery of fully human therapeutic antibodies against high‑value oncology targets.
Collaboration Key Points
| Element | Detail |
|---|---|
| Partnering Organizations | GemPharmatech & MSKCC |
| Platform Leveraged | NeoMab – next‑generation transgenic mice for rapid antibody discovery |
| Objective | Accelerate development of fully human therapeutic antibodies for unmet cancer indications |
| Scope | MSKCC researchers gain access to GemPharmatech’s full spectrum of pre‑clinical services and resources |
Why NeoMab Matters
- Speed & Precision – NeoMab mice are engineered for efficient human antibody generation, shortening lead‑time from target to candidate.
- Clinical Relevance – The platform delivers fully human molecules, reducing immunogenicity risks in human trials.
- Strategic Alignment – MSKCC’s extensive pre‑clinical infrastructure now combines with GemPharmatech’s unique biology, creating a powerful pipeline for high‑impact oncology therapies.
Forward‑Looking Statements
This release contains forward‑looking statements that are subject to risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech